GlassScriptPhysician profile
Alexander Pontikos
NPI 1235523168
$4,261.09
in general payments reported to CMS, 2019-2025
29 companies · $2,167 in 2025
The $2,167 reported for 2025 was more than what 81% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.94 · 2022: $390 · 2023: $626 · 2024: $1,047 · 2025: $2,167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,671 · Education: $169.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,670.65 |
| Education | $168.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,370.66 | 2021-2025 | |
| Janssen Biotech, INC. | $577.95 | 2022-2025 | Tremfya, Stelara, Simponi Aria |
| Takeda Pharmaceuticals U.S.A., INC. | $428.28 | 2021-2025 | Entyvio, Eohilia |
| Qol Medical, LLC | $241.03 | 2022-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $212.54 | 2022-2025 | Xifaxan, Plenvu |
| Sandoz INC. | $184.27 | 2023-2025 | Hyrimoz |
| Ardelyx, INC. | $173.28 | 2024-2025 | Ibsrela |
| Intercept Pharmaceuticals, INC. | $115.09 | 2022-2025 | Ocaliva |
| Merck Sharp & Dohme LLC | $113.10 | 2023-2024 | Dificid |
| Madrigal Pharmaceuticals | $104.13 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $97.69 | 2022-2025 | |
| Aimmune Therapeutics, INC. | $85.12 | 2024-2025 | Zenpep |
| Celgene Corporation | $61.46 | 2022-2024 | Zeposia |
| Pfizer INC. | $57.91 | 2022-2025 | |
| Daiichi Sankyo INC. | $53.54 | 2023-2024 | Injectafer |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $52.53 | 2025 | Omvoh |
| Phathom Pharmaceuticals, INC. | $51.01 | 2025 | Voquezna |
| Organon LLC | $41.76 | 2022-2024 | Renflexis |
| Ipsen Biopharmaceuticals, INC | $41.39 | 2024 | Iqirvo |
| Vivus LLC | $36.12 | 2025 | Qsymia |
| Biocon Biologics INC | $24.92 | 2025 | Yesintek |
| Boston Scientific Corporation | $21.71 | 2025 | Watchman Access System |
| Novo Nordisk INC | $20.13 | 2025 | Wegovy |
| Mauna Kea Technologies, INC. | $16.89 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $16.79 | 2022 | |
| Fresenius Kabi USA, LLC | $16.73 | 2023 | |
| Amgen INC. | $16.00 | 2022 | |
| Celltrion USA INC. | $14.73 | 2025 | Vegzelma |
| Evoke Pharma, INC. | $14.33 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alexander Pontikos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.